LEONABIO INC
LONANASDAQTrading Snapshot
- Day Range
- $3.46 – $3.54
- 52-Week Range
- $3.12 – $14.21
- Volume
- $4.26B
- Avg Volume
- $5.04B
- Shares Outstanding
- 9.4M
- Next Earnings
- Oct 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $955,812
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-19.72
- Dividend Yield
- —
- Dilution (1yr)
- +11.1%
Why Investors Own LONA
- ✓High-growth profile — revenue up +53.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 52% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LEONABIO INC
LONA
StockOtter · stockotter.spaceAbout LEONABIO INC
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Athira Pharma (NASDAQ:LONA) Stock Price Down 34.9% – Should You Sell?
Athira Pharma, Inc. (NASDAQ: LONA - Get Free Report) shares traded down 34.9% during mid-day trading on Friday. The company traded as low as $3.12 and last traded at $3.25. Approximately 343,726 shares were traded during
LeonaBio to Participate in Cantor Global Healthcare Conference 2026
BOTHELL, Wash., Sept. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs,
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast Cancer
BOTHELL, Wash., Aug. 12, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, t